Double-Punch immunotherapy trial aims to tame Tough-to-Treat blood cancer
NCT ID NCT06550895
Summary
This study is testing the safety and effectiveness of a combination of two immunotherapy drugs, ciltacabtagene autoleucel (a CAR-T cell therapy) and talquetamab, for people with high-risk multiple myeloma that has come back after several prior treatments. The main goal is to see how safe the combination is, while also checking if it can shrink the cancer and keep it away. It is for patients who have already tried at least three other treatment lines.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, 3084, Australia
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
Peter MacCallum Cancer Centre
Melbourne, 3000, Australia
-
Royal Prince Alfred Hospital
Camperdown, 2050, Australia
-
The Alfred Hospital
Melbourne, 3004, Australia
-
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.